[1] 郭峰, 庄小芳, 王晓波, 等. 三种肝纤维化无创诊断对慢性乙型肝炎进展性肝纤维化(≥F3)诊断价值评估. 肝脏, 2018, 23:235-239.
[2] 李文文, 孙朋, 陈豆豆,等. 雷帕霉素对自身免疫性肝炎小鼠及肝纤维化的防治作用及其机制. 中华肝脏病杂志, 2016, 24:368-374.
[3] 陈宵瑜, 杨长青. 肝纤维化发生机制研究新进展. 实用肝脏病杂志, 2016, 19:121-124.
[4] Nishikawa Y, Wang M, Carr BI. Changes in TGF-β receptors of rat hepatocytes during primary culture and liver regeneration: Increased expression of TGF-β receptors associated with increased sensitivity to TGF-β-mediated growth inhibition. J Cell Physiol, 2015, 176:612-623.
[5] 王川林, 刘娇, 戢敏, 等. 以肝星状细胞活化、凋亡为靶点干预肝纤维化的研究进展. 山东医药, 2018,58:110-113.
[6] Xiang S, Li M, Xie X, et al. Rapamycin inhibits epithelial-to-mesenchymal transition of peritoneal mesothelium cells through regulation of Rho GTPases. Febs J, 2016, 283:2309-2325.
[7] 李文文, 孙朋, 陈豆豆,等. 雷帕霉素对自身免疫性肝炎小鼠及肝纤维化的防治作用及其机制. 中华肝脏病杂志, 2016, 24:368-374.
[8] Bridle KR, Sobbe AL, de Guzman CE, et al. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2-/- mice. Liver Int, 2015, 35:1451-1463. |
